Organization, Plan of Business Operations (Details) - USD ($) $ / shares in Units, $ in Thousands |
Feb. 08, 2019 |
Sep. 30, 2019 |
Dec. 31, 2018 |
Nov. 12, 2018 |
|---|---|---|---|---|
| Accumulated deficit | $ (62,702) | $ (42,209) | ||
| Line of Credit [Member] | ||||
| Interim Financing Amount | $ 7,000 | $ 7,000 | ||
| Invagen Pharmaceuticals Inc [Member] | ||||
| Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | 5,833,333 | |||
| Business Acquisition, Share Price | $ 6.00 | |||
| Business Acquisition, Equity Interest Issued or Issuable, Value Assigned | $ 31,500 | $ 215,000 | ||
| Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners | 33.30% | |||
| Invagen Pharmaceuticals Inc [Member] | Common Stock [Member] | ||||
| Business Acquisition, Equity Interest Issued or Issuable, Value Assigned, Remaining Purchase Amount | $ 180,000 |
| X | ||||||||||
- Definition Business Acquisition, Equity Interest Issued or Issuable, Value Assigned, Remaining Purchase Amount No definition available.
|
| X | ||||||||||
- Definition Amount of interim financing receivable. No definition available.
|
| X | ||||||||||
- Definition Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of shares of equity interests issued or issuable to acquire entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination. No definition available.
|
| X | ||||||||||
- Definition The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity. No definition available.
|
| X | ||||||||||
- Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|